Steatosis, Steatohepatitis and Cancer Immunotherapy: An Intricate Story
Immune checkpoint inhibitors represent one of the most significant recent advances in clinical oncology, since they dramatically improved the prognosis of deadly cancers such as melanomas and lung cancer. Treatment with these drugs may be complicated by the occurrence of clinically-relevant adverse...
Main Authors: | Mauro Cataldi, Federica Manco, Giovanni Tarantino |
---|---|
Format: | Article |
Language: | English |
Published: |
MDPI AG
2021-11-01
|
Series: | International Journal of Molecular Sciences |
Subjects: | |
Online Access: | https://www.mdpi.com/1422-0067/22/23/12947 |
Similar Items
-
State of CD8+ T cells in progression from nonalcoholic steatohepatitis to hepatocellular carcinoma: From pathogenesis to immunotherapy
by: Xin Zhong, et al.
Published: (2023-09-01) -
Impaired Response to Immunotherapy in Non-Alcoholic Steatohepatitis-Related Hepatocellular Carcinoma?
by: Masatoshi Kudo
Published: (2021-07-01) -
Hepatic Steatosis and Steatohepatitis Is the Inevitability of Mixed Genesis
by: Yu.M. Stepanov
Published: (2014-11-01) -
Steatosis and steatohepatitis found in adults after death due to non-burn trauma
by: Paulo Reis-Júnior, et al.
Published: (2019-10-01) -
Chemotherapy-associated steatohepatitis
by: Lucy Meunier, et al.
Published: (2020-11-01)